Skip to content

Clinical Study on the Treatment of Postpartum Anemia With Compound E Jiao Jiang(cEJJ)

A Multicenter, Randomized, Double-blind, Parallel Controlled Clinical Study on the Efficacy and Safety of Compound E Jiao Jiang(cEJJ)in the Treatment of Postpartum Anemia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06175117
Enrollment
360
Registered
2023-12-18
Start date
2023-01-07
Completion date
2025-09-08
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Anemia

Brief summary

The goal of this clinical trial\] is to compare the effect of compound E Jiao Jiang(cEJJ)combined with iron decoction on postpartum anemia.The main questions it aims to answer are: To evaluate the effectiveness of compound E Jiao Jiang(cEJJ) in the treatment of postpartum anemia. To evaluate the safety of compound E Jiao Jiang(cEJJ) in the treatment of postpartum anemia. To explore the effect of compound ejiao decoction on improving anxiety, depression, sleep and fatigue in postpartum anemia patients. Participants will be randomly assigned (like flipping a coin) to either the trial group or the control group (with a 50% chance of being assigned to either group), where the trial group will receive the compound E Jiao Jiang(cEJJ) + ferrous succinate tablet, and the control group will receive the compound E Jiao Jiang(cEJJ)placebo + ferrous succinate tablet. The compound E Jiao Jiang(cEJJ)placebo is the same/similar to the compound E Jiao Jiang(cEJJ) in terms of appearance, smell and taste, but has no therapeutic effect.And participants need to return to the research center on time for relevant examinations according to the protocol requirements.

Interventions

DRUGcompound E Jiao Jiang(cEJJ)

compound E Jiao Jiang(cEJJ):20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.

DRUGcompound E Jiao Jiang(cEJJ) placebo

compound E Jiao Jiang(cEJJ) placebo:20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.

Sponsors

DongE E Jiao Coporation Limited
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Patients diagnosed with mild or moderate anemia (70g/L≤Hb \< 110g/L) within 1 week postpartum and suitable for oral drug therapy; 2. Age 18-45 years old (including 18 and 45); 3. Those who do not use other iron agents and Chinese medicine/Chinese medicine preparations that have the effect of invigorating qi and nourishing blood during the study; 4. Sign the subject's informed consent voluntarily.

Exclusion criteria

1. Postpartum hemorrhage and blood transfusion treatment; 2. Those who received intramuscular/intravenous iron therapy or transfused blood products/human blood albumin and other plasma volume dilators within 3 months prior to screening; 3. Patients who have taken blood tonics within 1 week before screening, including other iron preparations and Chinese medicine or Chinese medicine preparations; 4. People with previous blood diseases such as sickle cell anemia, thalassemia, aplastic anemia, megaloblastic anemia; 5. Severe preeclampsia during pregnancy; 6. Abortion occurs in this pregnancy; 7. Patients with a serious digestive disease, cardiovascular disease, immune system disease, or serious mental disorder that the investigator believes may adversely affect the safety of the subject and/or the effectiveness of the investigational drug; 8. Severe hepatic and renal insufficiency (ALT \>2×ULN, aspartate aminotransferase (AST)\>2×ULN, Urea (Urea)/ urea nitrogen (BUN)\>2×ULN, creatinine (Cr)\>1×ULN); 9. Those who have a history of alcohol abuse, drug abuse or drug use before; 10. Allergic to the experimental drug or known ingredient; 11. Participants who had participated in other clinical trials within 3 months before screening; 12. Those who, according to the judgment of the investigator, consider it inappropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin(Hb) change value6 weeksHb changes after 6 weeks of continuous medication

Secondary

MeasureTime frameDescription
The proportion of hemoglobin rising > 10g/L6 weeksThe proportion of Hb increased \>10g/L after 6 weeks of continuous administration
serum ferritin change value6 weeksserum ferritin changes after 6 weeks of continuous medication
Red Blood Cell(RBC) change value6 weeksRBC changes after 6 weeks of continuous medication
Hematocrit(HCT )change value6 weeksHCT changes after 6 weeks of continuous medication
Traditional Chinese Medicine symptom score(a self-made scale for Qi-blood Deficiency Syndrome) change value6 weeksThe TCM Qi and blood deficiency scale total score ranges from 0 to 54, and the higher the score, the more serious it is.
The proportion of hemoglobin returned to normal6 weeksHb returned to normal proportions after 6 weeks of continuous medication
The proportion of hemoglobin rising > 20g/L6 weeksThe proportion of Hb increased \>20g/L after 6 weeks of continuous administration
serum iron change value6 weeksserum iron changes after 6 weeks of continuous medication

Other

MeasureTime frameDescription
Pittsburgh sleep quality index(PSQI) change value6 weeksThe PSQI total score ranges from 0 to 21, and the higher the score, the worse the sleep quality.
The Functional Assessment of Chronic Illness Therapy-Fatigue(FACIT-F) change value6 weeksThe FACIT-F total score ranges from 0 to52, and the higher the score, the more fatigue.
Edinburgh Postnatal Depression(EPDS) change value6 weeksThe EPDS total score ranges from 0 to 30, and the higher the score, the severe the depression.
Self-rating Anxiety Scale(SAS)change value6 weeksThe SAS total score ranges from 0 to 80, and the higher the score, the greater the anxiety.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026